Axsome Therapeutics, Inc. - Common Stock (AXSM)

Competitors to Axsome Therapeutics, Inc. - Common Stock (AXSM)

Alkermes plc 

Alkermes focuses on developing innovative treatments for addiction and central nervous system disorders, making it a direct competitor to Axsome in the same therapeutic area. The company's established drug Vivitrol for opioid dependence and Aripiprazole for schizophrenia provides a competitive benchmark for Axsome's pipeline products. Alkermes' experience in integrating pharmacological and formulation technology gives it a slight edge in the market, although both companies are still navigating the same regulatory landscape.

Eli Lilly and Company 

Eli Lilly is a global leader in neuroscience therapies, notably in the treatment of depression and neurodegenerative diseases. As it develops well-established products such as Cymbalta (duloxetine) and others targeting mental health, Eli Lilly competes with Axsome by offering established therapies with extensive clinical data. Additionally, Eli Lilly's strong R&D capabilities, larger market presence, and broader portfolio give it a competitive edge in the neuroscience domain.

Evoke Pharma, Inc. 

Evoke Pharma is primarily focused on gastrointestinal diseases, but it aligns with Axsome in their commitment to developing condition-specific treatments. The competition arises not from overlapping therapeutic areas, but rather from a similar target market of focused pharmaceutical innovation and treatment efficacy. Evoke's recent push towards commercialization and specialty pharmacy arrangements poses a competitive landscape for Axsome, emphasizing the race for limited market opportunities despite differing therapeutic focuses.

H. Lundbeck A/S

Lundbeck is a global pharmaceutical company highly specialized in the treatment of psychiatric and neurological disorders. It competes with Axsome through its established portfolio and significant investments in R&D related to mental health. Lundbeck's existing drugs and its strong presence in Europe give it a robust competitive position, enabling them to leverage global partnerships for expanding treatment options in bipolar disorder and depression, areas of focus for Axsome as well.

Neurocrine Biosciences 

Neurocrine Biosciences develops and commercializes innovative therapies for neurological and endocrine diseases. They compete with Axsome in the realm of CNS disorders including movement disorders and psychiatric conditions. Neurocrine's established therapies such as Ingrezza (valbenazine) for tardive dyskinesia demonstrate their capacity to succeed in markets that Axsome is also targeting. Their clinical expertise and proactive research strategy position them as significant competitors in this field.